SynthesisFrontiers in medicine2026
Vimentin expression as a prognostic marker in pancreatic cancer: a systematic review and meta-analysis.
Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pancreatic Cancer-Derived Small Extracellular Vesicles Remodel Hepatic Pre-Metastatic Niche via Hybrid Epithelial-Mesenchymal States.International journal of molecular sciences · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Vimentin, a key component of the epithelial-to-mesenchymal transition (EMT), has been mechanistically implicated in the progression and poor prognosis of pancreatic ductal adenocarcinoma (PDAC). However, clinical studies investigating the prognostic significance of tumor-cell vimentin expression have yielded inconsistent results. This systematic review and meta-analysis aimed to precisely quantify the association between vimentin expression and key clinicopathological features, including overall survival (OS), tumor stage, lymph node status, and distant metastasis. Methods: A systematic search was conducted across PubMed, Web of Science, and Scopus, published before July 8th, 2025, yielding 443 articles. Following duplicate removal and two rounds of independent screening using Rayyan by two reviewers, with non-concordance resolved by a third, a total of nine articles met the inclusion criteria for the meta-analysis. Pooled effect sizes were calculated using Hazard Ratios (HRs) for OS and Odds Ratios (ORs) with 95% Confidence Intervals (CIs) for categorical outcomes. Heterogeneity was assessed using the Results: We demonstrated a statistically significant association between tumor-cell vimentin expression and reduced OS [pooled logHR = 1.39, 95% CI: (0.11, 2.68), Conclusion: While tumor-cell vimentin expression is significantly associated with poorer OS and lymph node involvement, high heterogeneity and potential publication bias necessitate caution. Current evidence suggests vimentin is a promising prognostic indicator, but its clinical utility as a standalone biomarker remains limited by a lack of methodological standardization. Systematic Review Registration: PROSPERO 2025 CRD420251127404. Available from https://www.crd.york.ac.uk/PROSPERO/view/CRD420251127404.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.